EXECUTIVE ENGAGEMENTS
POOL
608
Number of executives repeatedly engaged by snail & email outreach
INTERACTIONS
122
Interactions with Platform & by Email
PARTICIPANTS
24
Unique # Participated
VALIDATIONS
12
Responses Validated*
COMPANIES
33
Responses Validated*
* Login for a full stack data experience
DATE
APR 2021
TABLES
134
PAGES
197
EDITION
8
PRICE
USD 5600
CODE
MCP22378
*Engagement stats are ongoing and dynamic
HIGHLIGHTS & REPORT INDEX
Amid the COVID-19 crisis, the global market for Next Generation Sequencing (NGS) Data Analysis estimated at US$638.8 Million in the year 2020, is projected to reach a revised size of US$1.4 Billion by 2027, growing at aCAGR of 12.2% over the period 2020-2027. Services, one of the segments analyzed in the report, is projected to record 12.5% CAGR and reach US$836.2 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Software segment is readjusted to a revised 11.7% CAGR for the next 7-year period.
The Next Generation Sequencing (NGS) Data Analysis market in the U.S. is estimated at US$188.6 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$249.7 Million by the year 2027 trailing a CAGR of 11.7% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 10.7% and 10.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 8.9% CAGR.
SELECT PLAYERS
Agilent Technologies, Inc.; Bio-Rad Laboratories, Inc.; Congenica Ltd.; DNAnexus Inc.; Dnastar, Inc.; Eurofins Scientific; F. Hoffmann-La Roche Ltd.; Fabric Genomics, Inc.; Genuity Science; Golden Helix, Inc.; Illumina, Inc.; Intrexon Bioinformatics Germany GmbH; Pacific Biosciences of California, Inc.; Partek Incorporated; PierianDx; Qiagen; SciGenom Labs Pvt. Ltd.; Thermo Fisher Scientific, Inc.
SEGMENTS
» Component (Services, Software) » Workflow (Tertiary Data Analysis, Primary Data Analysis, Secondary Data Analysis) » Mode (In-House, Outsourced) » End-Use (Academic Research, Clinical Research, Pharma & Biotech Entities, Hospitals & Clinics, Other End-Uses)
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World
TABLE OF CONTENTS
| I. METHODOLOGY |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Influencer Market Insights |
| World Market Trajectories |
| Impact of Covid-19 and a Looming Global Recession |
| 2. FOCUS ON SELECT PLAYERS |
| 3. MARKET TRENDS & DRIVERS |
| 4. GLOBAL MARKET PERSPECTIVE |
| World Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020 & 2027 |
| World Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| World Current & Future Analysis for Software by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Software by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| World Current & Future Analysis for Pharma & Biotech Entities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Pharma & Biotech Entities by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| World Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| World Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| World Current & Future Analysis for Academic Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Academic Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| World Current & Future Analysis for Clinical Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Clinical Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| World Current & Future Analysis for Tertiary Data Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Tertiary Data Analysis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| World Current & Future Analysis for Primary Data Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Primary Data Analysis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| World Current & Future Analysis for Secondary Data Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Secondary Data Analysis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| World Current & Future Analysis for In-House by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for In-House by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| World Current & Future Analysis for Outsourced by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Outsourced by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| III. MARKET ANALYSIS |
| UNITED STATES |
| USA Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| USA 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Sales for Services and Software for the Years 2020 & 2027 |
| USA Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Pharma & Biotech Entities, Hospitals & Clinics, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| USA 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Entities, Hospitals & Clinics, Other End-Uses, Academic Research and Clinical Research for the Years 2020 & 2027 |
| USA Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| USA 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Sales for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2020 & 2027 |
| USA Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| USA 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Sales for In-House and Outsourced for the Years 2020 & 2027 |
| CANADA |
| Canada Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Canada 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Sales for Services and Software for the Years 2020 & 2027 |
| Canada Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Pharma & Biotech Entities, Hospitals & Clinics, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Canada 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Entities, Hospitals & Clinics, Other End-Uses, Academic Research and Clinical Research for the Years 2020 & 2027 |
| Canada Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Canada 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Sales for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2020 & 2027 |
| Canada Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Canada 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Sales for In-House and Outsourced for the Years 2020 & 2027 |
| JAPAN |
| Japan Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Japan 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Sales for Services and Software for the Years 2020 & 2027 |
| Japan Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Pharma & Biotech Entities, Hospitals & Clinics, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Japan 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Entities, Hospitals & Clinics, Other End-Uses, Academic Research and Clinical Research for the Years 2020 & 2027 |
| Japan Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Japan 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Sales for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2020 & 2027 |
| Japan Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Japan 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Sales for In-House and Outsourced for the Years 2020 & 2027 |
| CHINA |
| China Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| China 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Sales for Services and Software for the Years 2020 & 2027 |
| China Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Pharma & Biotech Entities, Hospitals & Clinics, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| China 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Entities, Hospitals & Clinics, Other End-Uses, Academic Research and Clinical Research for the Years 2020 & 2027 |
| China Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| China 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Sales for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2020 & 2027 |
| China Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| China 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Sales for In-House and Outsourced for the Years 2020 & 2027 |
| EUROPE |
| Europe Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| Europe 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2020 & 2027 |
| Europe Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Europe 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Sales for Services and Software for the Years 2020 & 2027 |
| Europe Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Pharma & Biotech Entities, Hospitals & Clinics, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Europe 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Entities, Hospitals & Clinics, Other End-Uses, Academic Research and Clinical Research for the Years 2020 & 2027 |
| Europe Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Europe 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Sales for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2020 & 2027 |
| Europe Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Europe 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Sales for In-House and Outsourced for the Years 2020 & 2027 |
| FRANCE |
| France Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| France 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Sales for Services and Software for the Years 2020 & 2027 |
| France Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Pharma & Biotech Entities, Hospitals & Clinics, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| France 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Entities, Hospitals & Clinics, Other End-Uses, Academic Research and Clinical Research for the Years 2020 & 2027 |
| France Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| France 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Sales for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2020 & 2027 |
| France Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| France 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Sales for In-House and Outsourced for the Years 2020 & 2027 |
| GERMANY |
| Germany Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Germany 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Sales for Services and Software for the Years 2020 & 2027 |
| Germany Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Pharma & Biotech Entities, Hospitals & Clinics, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Germany 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Entities, Hospitals & Clinics, Other End-Uses, Academic Research and Clinical Research for the Years 2020 & 2027 |
| Germany Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Germany 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Sales for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2020 & 2027 |
| Germany Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Germany 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Sales for In-House and Outsourced for the Years 2020 & 2027 |
| ITALY |
| Italy Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Italy 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Sales for Services and Software for the Years 2020 & 2027 |
| Italy Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Pharma & Biotech Entities, Hospitals & Clinics, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Italy 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Entities, Hospitals & Clinics, Other End-Uses, Academic Research and Clinical Research for the Years 2020 & 2027 |
| Italy Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Italy 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Sales for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2020 & 2027 |
| Italy Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Italy 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Sales for In-House and Outsourced for the Years 2020 & 2027 |
| UNITED KINGDOM |
| UK Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| UK 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Sales for Services and Software for the Years 2020 & 2027 |
| UK Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Pharma & Biotech Entities, Hospitals & Clinics, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| UK 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Entities, Hospitals & Clinics, Other End-Uses, Academic Research and Clinical Research for the Years 2020 & 2027 |
| UK Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| UK 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Sales for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2020 & 2027 |
| UK Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| UK 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Sales for In-House and Outsourced for the Years 2020 & 2027 |
| REST OF EUROPE |
| Rest of Europe Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Rest of Europe 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Sales for Services and Software for the Years 2020 & 2027 |
| Rest of Europe Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Pharma & Biotech Entities, Hospitals & Clinics, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Rest of Europe 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Entities, Hospitals & Clinics, Other End-Uses, Academic Research and Clinical Research for the Years 2020 & 2027 |
| Rest of Europe Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Rest of Europe 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Sales for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2020 & 2027 |
| Rest of Europe Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Rest of Europe 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Sales for In-House and Outsourced for the Years 2020 & 2027 |
| ASIA-PACIFIC |
| Asia-Pacific Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Sales for Services and Software for the Years 2020 & 2027 |
| Asia-Pacific Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Pharma & Biotech Entities, Hospitals & Clinics, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Entities, Hospitals & Clinics, Other End-Uses, Academic Research and Clinical Research for the Years 2020 & 2027 |
| Asia-Pacific Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Sales for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2020 & 2027 |
| Asia-Pacific Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Sales for In-House and Outsourced for the Years 2020 & 2027 |
| REST OF WORLD |
| Rest of World Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Rest of World 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Sales for Services and Software for the Years 2020 & 2027 |
| Rest of World Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Pharma & Biotech Entities, Hospitals & Clinics, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Rest of World 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Entities, Hospitals & Clinics, Other End-Uses, Academic Research and Clinical Research for the Years 2020 & 2027 |
| Rest of World Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Rest of World 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Sales for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2020 & 2027 |
| Rest of World Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Rest of World 7-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Sales for In-House and Outsourced for the Years 2020 & 2027 |
| IV. COMPETITION |
| Total Companies Profiled: 33 |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com